Sobi Reports Strong Q2 2026 Growth on Pipeline Progress
Event summary
- Total revenue increased 29% at constant exchange rates (CER) to SEK 7,842M.
- Haematology and Immunology revenues grew 27% and 37% respectively at CER.
- Adjusted EBITA margin expanded to 35% from 34%, with EBIT reaching SEK 2,843M.
- Positive Phase 3 results for Pozdeutinurad in gout; NASP received CRL on manufacturing.
- 2026 revenue outlook raised to mid-to high-teens growth at CER.
The big picture
Sobi's Q2 2026 results highlight strong commercial momentum in haematology and immunology, driven by key products like Altuvoct and Gamifant. The company's ability to sustain double-digit revenue growth while expanding margins reflects strategic focus on high-value therapies. Positive pipeline updates for Pozdeutinurad and NASP underscore the importance of regulatory milestones in shaping long-term market positioning.
What we're watching
- Pipeline Execution
- Whether Pozdeutinurad's positive Phase 3 results translate into regulatory approval and commercial success.
- Regulatory Dynamics
- The pace at which NASP resolves manufacturing issues following the CRL to advance uncontrolled gout treatment.
- Margin Sustainability
- How Sobi maintains its expanded EBITA margin amid accelerated revenue growth and strategic portfolio expansion.
Related topics